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INTRODUCTION: Rhabdomyolysis associated with the use of pravastatin has been demonstrated to be a
rarebutpotentially life-threateningadverseeffectof statins.Here,wereport a rare caseof rhabdomyolysis
and purpura fulminans in a patient who had used pravastatin and developed chronic renal failure (CRF)
necessitating the initiation of dialysis.
PRESENTATION OF CASE: We present the case of an 86-year-old man with chronic kidney disease (CKD)
treated with dialysis who was admitted with back pain. He was prescribed and took pravastatin for
almost 3 years to treat hyperlipidemia. He received hemodialysis therapy 7 times prior to presentation.
Laboratory values included a serum creatine concentration of 6.6mg/dl and a creatinine phosphokinase
(CPK) concentration of 2350 IU/L. An abdominal computed tomography scan showed swollen muscles
with reduced muscle density and air density in the multiﬁdus muscle. Two days after admission, he
had large, tender ecchymotic lesions and purpuric progressive skin necrosis over the back, abdomen,
and upper and lower extremities. The patient died 6 days after the initial admission due to disseminated
intravascular coagulation (DIC). Basedon theseﬁndingsand theclinical history, adiagnosis ofpravastatin-
induced rhabdomyolysis and purpura fulminans was made.
DISCUSSION: The long-term use of statin therapy and the initiation of dialysis therapy due to ESRD, fol-
lowed by a rapid onset of rhabdomyolysis within 6 days, is indicative of an elevated statin concentration.
CONCLUSION: We report an extremely rare case of pravastatin-induced rhabdomyolysis and purpura
fulminans with DIC in a patient with CRF.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The ability of statins to reduce the risk of cardiovascularmorbid-
ity and mortality in patients with dyslipidemia is well established
[1]. In general, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors (statins) are well tolerated bymost users
[2]. Statins are also associated with rhabdomyolysis, which may
raise concerns about possible adverse drug interactions. The typical
clinical presentation of rhabdomyolysis includesmuscleweakness,
myalgias and dark-colored urine due to myoglobinuria. The diag-
nosis is usually based on elevated serum skeletal muscle enzyme
∗ Corresponding author. Tel.: +81 166 85 2222; fax: +81 166 58 9008.
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levels [3]. Purpura fulminans is an acute illness characterized by
rapidly progressive dermal vascular thrombosis and disseminated
intravascular coagulation (DIC), leading to hemorrhagic skin necro-
sis and soft tissue necrosis.
We report an extremely rare case of rhabdomyolysis of the
multiﬁdus muscle with pravastatin monotherapy in a patient with
chronic renal failure (CRF) thatmayhave resulted in purpura ﬂumi-
nanswith DIC. Here, we report this rare case and review the related
literature.
2. Presentation of case
The patient was an 86-year-old man with chronic kidney dis-
ease (CKD) who also had hyperlipidemia. His past medical history
was signiﬁcant for pravastatin treatment (10mg once daily) for
http://dx.doi.org/10.1016/j.ijscr.2015.01.042
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. (a): An abdominal computed tomography (CT) scan showing a large area of low attenuation in the multiﬁdus muscle (arrow). (b): The multiﬁdus muscle was slightly
edematous. No calciﬁcation was observed.
almost 3 years. He was diagnosed with end stage renal disease
(ESRD) and started hemodialysis three times perweek. He received
hemodialysis therapy 7 times before presentation. Before the ini-
tiation of dialysis therapy, the patient’s serum creatinine was
4.7mg/dL, urea 122mmol/L, and the thyroid-stimulating hormone
concentration and liver function were within normal limits. Past
medical history included the following pertinent negatives: no
recent viral illness, history of trauma, or epilepsy, and the absence
of any other medications that could potentially be associated with
rhabdomyolysis.Uponadmission, thepatienthadgeneralizedmus-
cle pain and back pain and the following laboratory values: white
blood cell count, 7800mm3; platelet count, 28,000l; Aspartate
aminotransferase (AST), 77U/L; alanine aminotransferase (ALT),
22U/L; LDH, 356U/L; triglycerides, 107mg/dL; total cholesterol,
119mg/dL; myoglobin, 3000g/mL; creatine, 6.6mg/dL; and cre-
atinine phosphokinase (CPK), 2350 IU/L. The elevated CPK was not
cardiac in origin because both electrocardiography andmyocardial
enzymes markers were within normal limits. Lab values demon-
strated evidence of disseminated intravascular coagulation (DIC)
and were as follows: prothrombin time, 18.3 s; active partial pro-
thrombin time, 38.5 s; ﬁbrinogendegradationproduct, 24.1g/mL;
and D-dimer, 12.9mg/mL. Two days after admission, he had large,
tender ecchymotic lesions and purpuric, progressive skin necro-
sis over the back, abdomen, and upper and lower extremities. An
abdominal computed tomography (CT) scan showed swollen mus-
cles with reduced muscle density and air density in the multiﬁdus
muscle (Fig. 1 a and b) [4]. No calciﬁcation was observed in the
multiﬁdus muscle. These ﬁndings, along with the clinical history,
conﬁrmedadiagnosis of pravastatin- induced rhabdomyolysiswith
purpura fulminans. The patient died 6 days after the initial admis-
sion due to DIC (Fig. 2 a and b).
3. Discussion
The most noteworthy adverse reactions associated with statins
are elevations in myopathy and rhabdomyolysis, which is charac-
terized bymassivemuscle necrosis,myoglobinuria, and acute renal
failure [5]. In a recently published review, it was suggested that
myopathy occurred in 20% of patients receiving statin therapy [6].
The risk of rhabdomyolysiswith statinmonotherapy is dose related
[7,8]. The adverse events submitted to the FDA, including myal-
gia, rhabdomyolysis, an increase in CPK level and other muscular
events,were associatedwith pravastatin, simvastatin, atorvastatin,
and rosuvastatin. These eventsweremore noteworthy for rosuvas-
tatin than pravastatin and atorvastatin [9]. Acute renal failure was
also associated with all 4 statins [9].
The clinical manifestations of rhabdomyolysis associated with
statins are nonspeciﬁc. This condition presents as myalgias, weak-
ness, fatigue, and dark-colored urine,which usually developwithin
a few days of starting the treatment. Pravastatin monotherapy is
associated with the potentially fatal side effect of rhabdomyolysis,
which induces DIC and purpura fulminans in our case. Rhabdomy-
olysis associated with pravastatin monotherapy is extremely rare
and may result in myoglobinuria with acute renal failure.
Several factors have been identiﬁed that increase the risk for
both myopathy and rhabdomyolysis, including advanced age, CRF,
metabolic disorders, major surgery, and alcohol abuse [10–12].
Statins are safe and valuable drugs in patients with renal insufﬁ-
ciency. However, it may be prudent to limit the dose of pravastatin
(<20mg/day) as well as simvastatin (<10mg/day) in patients with
a GFR below 10mL/min and prior to dialysis [13]. The side effects
of statin treatment include gastrointestinal complaints, gallstones,
and skin reactions, all of which are tolerable and reversible.
Fig. 2. (a) and (b): Ecchymotic lesions and necrotic purpura on the upper and lower extremities, back, and abdomen.
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The mechanism of rhabdomyolysis with statins is poorly
deﬁned. The occurrence is known to increase with dose concentra-
tion [7,8]. Sakamoto [14] suggested that ﬂuvastatin and pravastatin
induced the formation of numerous vacuoles in themyoﬁbers after
72h of treatment in rats and inactivation of Rab GPTase, which is
involved in intracellularmembrane transport and is a crucial factor
in statin-induced-morphrological abnormality in the skeletal mus-
cle ﬁbers. This risk increases in patients taking concomitant drugs
that inhibit the cytochrome P450 (mainly CYP2C9 or CYP3A4)-
related statin metabolism such as azole antifungals, cyclosporine,
ﬁbrates, macrolides, and non- dihydropyridine calcium channel
blockers [14,15]. Although pravastatin is primary eliminated by
sulfation, all other available statins are metabolized by the CYP
system [15–17]. The metabolic processes include phase I oxida-
tion (mediated by CYP) isoenzymes and phase II glucuronidation
(mediated by UDP glucuronosyl transferase). Pravastatin has no
phase metabolism and is minimally metabolized by phase II glu-
curonidation.Most statins areeliminated throughbiliaryexcretion;
however, pravastatin is partially eliminated by renal excretion.
Inhibition of statin metabolism (Phase I or II) and/or active mem-
brane transportmay result in elevated statin concentration and has
the potential to increase the risk for statin-related adverse events.
In our case, the long-term use of statin therapy and the initia-
tion of dialysis therapy due to ESRD, followed by a rapid onset of
rhabdomyolysis within 6 days, is indicative of an elevated statin
concentration. However, experience with this situation is limited,
particularly in a patient with severe impairment of renal function
requiringdialysis. It is thought that drugormetabolic accumulation
and uremia-related muscle injury increase the risk of myositis.
The CT ﬁndings of rhabdomyolysis revealed either focal areas
of hypodensity or hyperdensity consistent with calciﬁcation in the
affected muscles. Focal hypodense areas are usually explained by
edematous or necroticmuscles in the acute phase of rhabdomyoly-
sis [4,18]. A CT scan can distinguish normalmuscles from abnormal
muscles and can clearly demonstrate necrosis in our case.
Purpura fulminans has been reported as a complication of over-
whelming infection with Neisseria meningitidis or varicella, and
more recently Streptococcus pneumonia [19]. Purpura fulminans
results inmicrovascular thrombosiswithhemorrhagic skin and soft
tissue necrosis. Coagulation abnormalities in sepsis or rhabdomy-
olysis range from a small decrease in platelet count and subclinical
prolongation of global clotting times to fulminant DIC, which is
characterized by simultaneouswhisperedmicrovascular thrombo-
sis and profuse bleeding from various sites. The pathogenesis of
purpura fulminans with digital gangrene is unclear and thought
to be related to the development of DIC [19]. The combination of
widespread gangrene and laboratory evidence ofDIC conﬁrmed the
diagnosis of purpura fulminans in our case. In dialysis patients, the
situation is different and the risk of drugs and metabolite accumu-
lation ismost likelymore severe. To the best of our knowledge, this
is the ﬁrst report of pravastatin monotherapy resulting in rhab-
domyolysis of the multiﬁdus muscle and purpura fulminans with
DIC.
In summery, pravastatin monotherapy is associated with the
potentially fatal side effect of rhabdomyolysis in a patient with
chronic renal failure. We report an extremely rare case of
pravastatin-induced rhabdomyolysis and purpura fulminans with
DIC in a patient with CRF. Early diagnosis and treatment are essen-
tial to improve the outcome. Diagnosis requires a high degree of
clinical suspicion.
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